» Articles » PMID: 36514940

Role of PCIF1-mediated 5'-cap N6-methyladeonsine MRNA Methylation in Colorectal Cancer and Anti-PD-1 Immunotherapy

Overview
Journal EMBO J
Date 2022 Dec 14
PMID 36514940
Authors
Affiliations
Soon will be listed here.
Abstract

Adenosine N6-methylation (m6A) and N6,2'-O-dimethylation (m6Am) are regulatory modifications of eukaryotic mRNAs. m6Am formation is catalyzed by the methyl transferase phosphorylated CTD-interacting factor 1 (PCIF1); however, the pathophysiological functions of this RNA modification and PCIF1 in cancers are unclear. Here, we show that PCIF1 expression is upregulated in colorectal cancer (CRC) and negatively correlates with patient survival. CRISPR/Cas9-mediated depletion of PCIF1 in human CRC cells leads to loss of cell migration, invasion, and colony formation in vitro and loss of tumor growth in athymic mice. Pcif1 knockout in murine CRC cells inhibits tumor growth in immunocompetent mice and enhances the effects of anti-PD-1 antibody treatment by decreasing intratumoral TGF-β levels and increasing intratumoral IFN-γ, TNF-α levels, and tumor-infiltrating natural killer cells. We further show that PCIF1 modulates CRC growth and response to anti-PD-1 in a context-dependent mechanism with PCIF1 directly targeting FOS, IFITM3, and STAT1 via m6Am modifications. PCIF1 stabilizes FOS mRNA, which in turn leads to FOS-dependent TGF-β regulation and tumor growth. While during immunotherapy, Pcif1-Fos-TGF-β, as well as Pcif1-Stat1/Ifitm3-IFN-γ axes, contributes to the resistance of anti-PD-1 therapy. Collectively, our findings reveal a role of PCIF1 in promoting CRC tumorigenesis and resistance to anti-PD-1 therapy, supporting that the combination of PCIF1 inhibition with anti-PD-1 treatment is a potential therapeutic strategy to enhance CRC response to immunotherapy. Finally, we developed a lipid nanoparticles (LNPs) and chemically modified small interfering RNAs (CMsiRNAs)-based strategy to silence PCIF1 in vivo and found that this treatment significantly reduced tumor growth in mice. Our results therefore provide a proof-of-concept for tumor growth suppression using LNP-CMsiRNA to silence target genes in cancer.

Citing Articles

The epitranscriptional factor PCIF1 orchestrates CD8 T cell ferroptosis and activation to control antitumor immunity.

Xiang B, Zhang M, Li K, Zhang Z, Liu Y, Gao M Nat Immunol. 2025; 26(2):252-264.

PMID: 39762445 DOI: 10.1038/s41590-024-02047-w.


Decoding mAm by simultaneous transcription-start mapping and methylation quantification.

Liu J, Hawley B, Nicholson L, Jaffrey S bioRxiv. 2024; .

PMID: 39677659 PMC: 11642800. DOI: 10.1101/2024.10.16.618717.


Cap-specific terminal N6-methyladeonsine methylation of RNA mediated by PCIF1 and possible therapeutic implications.

Zeng H, Wu Y, Long X Genes Dis. 2024; 12(1):101181.

PMID: 39524541 PMC: 11550742. DOI: 10.1016/j.gendis.2023.101181.


Cap-Specific mAm Methyltransferase PCIF1/CAPAM Regulates mRNA Stability of and through the mA Methyltransferase Activity.

Sugita A, Kano R, Ishiguro H, Yanagisawa N, Kuruma S, Wani S Cells. 2024; 13(20.

PMID: 39451207 PMC: 11506431. DOI: 10.3390/cells13201689.


m6Am Methyltransferase PCIF1 Promotes LPP3 Mediated Phosphatidic Acid Metabolism and Renal Cell Carcinoma Progression.

Luo W, Xu Z, Li F, Ding L, Wang R, Lin Y Adv Sci (Weinh). 2024; 11(46):e2404033.

PMID: 39422663 PMC: 11633504. DOI: 10.1002/advs.202404033.


References
1.
Yang S, Wei J, Cui Y, Park G, Shah P, Deng Y . mA mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019; 10(1):2782. PMC: 6592937. DOI: 10.1038/s41467-019-10669-0. View

2.
Han D, Liu J, Chen C, Dong L, Liu Y, Chang R . Anti-tumour immunity controlled through mRNA mA methylation and YTHDF1 in dendritic cells. Nature. 2019; 566(7743):270-274. PMC: 6522227. DOI: 10.1038/s41586-019-0916-x. View

3.
Boulias K, Toczydlowska-Socha D, Hawley B, Liberman N, Takashima K, Zaccara S . Identification of the mAm Methyltransferase PCIF1 Reveals the Location and Functions of mAm in the Transcriptome. Mol Cell. 2019; 75(3):631-643.e8. PMC: 6703822. DOI: 10.1016/j.molcel.2019.06.006. View

4.
Liu J, Yue Y, Han D, Wang X, Fu Y, Zhang L . A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2013; 10(2):93-5. PMC: 3911877. DOI: 10.1038/nchembio.1432. View

5.
Otegbeye F, Ojo E, Moreton S, Mackowski N, Lee D, de Lima M . Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS One. 2018; 13(1):e0191358. PMC: 5771627. DOI: 10.1371/journal.pone.0191358. View